Risk of Invasive Escherichia Coli (E. Coli) Disease After Elective Urologic Procedures Among Older Adults in the United States

Overview

Journal Infect Dis Ther

Date 2025 Feb 7

PMID 39918690

Authors

Maureen P Neary

Maryaline Catillon

Nina Ahmad

Marjolaine Gauthier-Loiselle

Jeroen Geurtsen

Alice Qu

Corinne Willame

Martin Cloutier

Antoine C El Khoury

Elie Saade

Affiliations

Soon will be listed here.

Abstract

Introduction: Little is known about the risk of invasive E. coli disease (IED) after elective urologic procedures. We estimated the risk of IED after selected urologic procedures in patients with or without antibiotic prophylaxis, and in controls with no urologic or other surgical procedures.

Methods: The Komodo Research Database (01/01/2021-06/30/2023) was used to identify patients ≥ 60 years old with selected urological procedures (index: first urologic procedure date) and randomly selected controls without surgical procedures (index: random date). Patients with urologic procedures were classified into two cohorts based on whether or not they received antibiotic prophylaxis within 14 days prior to and on index date. Entropy balancing adjusted for differences between groups in selected patient characteristics over 6 months pre-index (baseline). IED rates within 30 days post-index were assessed based on recorded diagnosis of E. coli sepsis (ICD-10-CM: A41.51); odds ratios (OR) were estimated using weighted logistic regression. Sensitivity analyses within 90 days and using broader claims-based algorithm for IED were performed.

Results: Overall, 141,418 patients had urologic procedures with antibiotic prophylaxis, 200,062 had them without antibiotic prophylaxis, and 424,254 had no procedures. Within 30 days post-index, IED rates were 0.48% and 0.72% among patients with or without antibiotic prophylaxis, respectively, vs. 0.02% among those without any procedures. Among patients with urologic procedures, > 70% of IED events occurred within 30 days. Patients who had urologic procedures without prophylaxis had a higher risk of developing IED than those with prophylaxis (OR = 1.50, 95% confidence interval [CI: 1.37-1.65]), while patients without any procedures had a lower risk than those with urologic procedures and prophylaxis (OR = 0.04, 95% CI [0.03-0.05]). Similar results were obtained in sensitivity analyses.

Conclusions: Urologic procedures were associated with an increased IED risk even with antibiotic prophylaxis. Results suggest an unmet need for additional preventative measures to reduce the burden of IED after urologic procedures.

References

Kaper J, Nataro J, Mobley H . Pathogenic Escherichia coli. Nat Rev Microbiol. 2004; 2(2):123-40. DOI: 10.1038/nrmicro818. View

Russo T, Johnson J . Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC. J Infect Dis. 2000; 181(5):1753-4. DOI: 10.1086/315418. View

Verboom D, Varkila M, Morrow B, Davies T, Ibarra de Palacios P, Poolman J . O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands. Vaccine. 2021; 39(12):1670-1674. DOI: 10.1016/j.vaccine.2021.02.031. View

Rosenberg S, Bonten M, Haazen W, Spiessens B, Abbanat D, Go O . Epidemiology and O-Serotypes of Extraintestinal Pathogenic Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter Study. J Urol. 2020; 205(3):826-832. DOI: 10.1097/JU.0000000000001425. View

Saade E, Gravenstein S, Donskey C, Wilson B, Spiessens B, Abbanat D . Characterization of Escherichia coli isolates potentially covered by ExPEC4V and ExPEC10V, that were collected from post-transrectal ultrasound-guided prostate needle biopsy invasive urinary tract and bloodstream infections. Vaccine. 2020; 38(33):5100-5104. DOI: 10.1016/j.vaccine.2020.06.024. View

Poolman J, Wacker M . Extraintestinal Pathogenic Escherichia coli, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field. J Infect Dis. 2015; 213(1):6-13. PMC: 4676548. DOI: 10.1093/infdis/jiv429. View

Rhee C, Kadri S, Dekker J, Danner R, Chen H, Fram D . Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use. JAMA Netw Open. 2020; 3(4):e202899. PMC: 7163409. DOI: 10.1001/jamanetworkopen.2020.2899. View

Doua J, Geurtsen J, Rodriguez-Bano J, Cornely O, Go O, Gomila-Grange A . Epidemiology, Clinical Features, and Antimicrobial Resistance of Invasive Disease in Patients Admitted in Tertiary Care Hospitals. Open Forum Infect Dis. 2023; 10(2):ofad026. PMC: 9933942. DOI: 10.1093/ofid/ofad026. View

Fay K, Sapiano M, Gokhale R, Dantes R, Thompson N, Katz D . Assessment of Health Care Exposures and Outcomes in Adult Patients With Sepsis and Septic Shock. JAMA Netw Open. 2020; 3(7):e206004. PMC: 7341174. DOI: 10.1001/jamanetworkopen.2020.6004. View

10.

Weerdenburg E, Davies T, Morrow B, Zomer A, Hermans P, Go O . Global Distribution of O Serotypes and Antibiotic Resistance in Extraintestinal Pathogenic Escherichia coli Collected From the Blood of Patients With Bacteremia Across Multiple Surveillance Studies. Clin Infect Dis. 2022; 76(3):e1236-e1243. PMC: 9907479. DOI: 10.1093/cid/ciac421. View

11.

de Kraker M, Jarlier V, Monen J, Heuer O, van de Sande N, Grundmann H . The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. Clin Microbiol Infect. 2012; 19(9):860-8. DOI: 10.1111/1469-0691.12028. View

12.

Laupland K, Church D . Population-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev. 2014; 27(4):647-64. PMC: 4187633. DOI: 10.1128/CMR.00002-14. View

13.

Russo T, Johnson J . Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes Infect. 2003; 5(5):449-56. DOI: 10.1016/s1286-4579(03)00049-2. View

14.

Bonten M, Johnson J, van den Biggelaar A, Georgalis L, Geurtsen J, Ibarra de Palacios P . Epidemiology of Escherichia coli Bacteremia: A Systematic Literature Review. Clin Infect Dis. 2020; 72(7):1211-1219. DOI: 10.1093/cid/ciaa210. View

15.

Hernandez-Pastor L, Geurtsen J, Baugh B, El Khoury A, Kalu N, Gauthier-Loiselle M . Clinical burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United States. BMC Infect Dis. 2023; 23(1):550. PMC: 10464165. DOI: 10.1186/s12879-023-08479-3. View

16.

Hernandez-Pastor L, Geurtsen J, Baugh B, El Khoury A, Kalu N, Krishnarajah G . Economic burden of invasive disease among older adult patients treated in hospitals in the United States. J Manag Care Spec Pharm. 2023; 29(8):873-883. PMC: 10397329. DOI: 10.18553/jmcp.2023.29.8.873. View

17.

Townsend N, Robinson T . Surgical Risk and Comorbidity in Older Urologic Patients. Clin Geriatr Med. 2015; 31(4):591-601. DOI: 10.1016/j.cger.2015.06.009. View

18.

Lightner D, Wymer K, Sanchez J, Kavoussi L . Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis. J Urol. 2019; 203(2):351-356. DOI: 10.1097/JU.0000000000000509. View

19.

Feliciano J, Teper E, Ferrandino M, Macchia R, Blank W, Grunberger I . The incidence of fluoroquinolone resistant infections after prostate biopsy--are fluoroquinolones still effective prophylaxis?. J Urol. 2008; 179(3):952-5. DOI: 10.1016/j.juro.2007.10.071. View

20.

Liss M, Chang A, Santos R, Nakama-Peeples A, Peterson E, Osann K . Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J Urol. 2011; 185(4):1283-8. PMC: 4063558. DOI: 10.1016/j.juro.2010.11.088. View